Telix Faces Pricing Pressure Amid 53% Revenue Growth and Clinical Milestones
Telix Pharmaceuticals reports a robust 53% revenue jump in Q3 2025 and raises its full-year guidance, underpinned by key reimbursement wins and expanding clinical programs.
- Q3 2025 revenue hits US$206 million, up 53% year-over-year
- FY 2025 revenue guidance increased to US$800–820 million
- Gozellix gains full CMS reimbursement in the US from October 2025
- Illuccix approved in 19 European markets with ongoing commercial launches
- Multiple clinical trials advancing, including ProstACT Phase 3 and BiPASS prostate cancer study
Strong Revenue Growth and Upgraded Guidance
Telix Pharmaceuticals has delivered a compelling financial performance in the third quarter of 2025, reporting unaudited group revenue of approximately US$206 million. This marks a striking 53% increase compared to the same period last year, reflecting the company’s successful commercial execution and expanding market footprint. Buoyed by this momentum, Telix has raised its full-year revenue guidance to a range of US$800 million to US$820 million, up from the previous US$770 million to US$800 million forecast.
Key Commercial Milestones Drive Momentum
A pivotal development underpinning Telix’s growth is the full reimbursement of Gozellix by the US Centers for Medicare and Medicaid Services (CMS), effective 1 October 2025. This includes a Level II HCPCS code and Transitional Pass-Through payment status, enhancing patient access and reimbursement certainty. Gozellix, alongside Illuccix, positions Telix uniquely as the only company with two FDA-approved PSMA imaging agents, enabling broader market penetration and customer choice.
On the European front, Illuccix has secured approval in 19 markets, including the United Kingdom, Germany, France, and several Nordic countries, with commercial launches underway. This geographic expansion is a significant step in establishing Telix’s presence in the competitive prostate cancer imaging space.
Advancing Clinical Pipeline and Research Investment
Telix continues to advance its therapeutic pipeline with notable progress in multiple clinical trials. The ProstACT Global Phase 3 trial for its lead prostate cancer therapy candidate has completed Part 1 enrollment, with Part 2 now open in several countries including Australia, Canada, and China. Early safety and dosimetry data are anticipated following patient monitoring.
Additional trials such as LUTEON for renal cell carcinoma, IPAX-BrIGHT for glioblastoma, and SOLACE for bone pain management are progressing, reflecting Telix’s diversified approach to oncology and rare diseases. The company has also increased its research and development expenditure guidance by 20% to 25% for FY 2025, signaling a commitment to innovation and pipeline expansion.
Operational and Corporate Highlights
Operationally, Telix has secured radiation licenses for its manufacturing facilities in Melbourne and Yokohama, preparing for commercial-scale production of critical medical isotopes. The company also completed its final royalty payment to ANMI, the original developer of Illuccix technology, through a buy-out option enabled by strong sales performance.
CEO Dr. Christian Behrenbruch highlighted the company’s strategic positioning, noting stabilizing pricing pressures and a growing customer base as Telix enters the final quarter of 2025 with confidence. The dual PSMA imaging product strategy is expected to enhance market share and production flexibility.
Bottom Line?
With robust revenue growth and strategic reimbursement wins, Telix is poised to deepen its market impact as clinical data and new launches unfold.
Questions in the middle?
- How will competitive pricing pressures evolve in the PSMA imaging market?
- What insights will the upcoming ProstACT Part 1 safety and dosimetry data reveal?
- When can investors expect FDA resubmissions for Pixclara and Zircaix imaging agents?
